Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (72 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > CLARIFICATION NEEDED FROM CO.
View:
Post by Tarbaby on Aug 21, 2024 5:10pm

CLARIFICATION NEEDED FROM CO.

By stating that Metformin can potentially activate Rutherrin in a patient with cancer to destroy that cancer even as an outpatient  does that not imply that Rutherrin is safe as a medicine given to a human along with Metformin..?? I read it that way.
This should be the BIGGEST NEWS in the entire cancer field and the stock should be soaring..whats wrong here..?
Comment by Longholder99 on Aug 21, 2024 5:38pm
To be clear.  The company has stated that Metformin does activate Rutherin as demonstrated in a preclinical study.  Does activate....not potentially.  Also, Rutherin is not yet FDA approved so it feels like after the 57M share dilution passes us by when that many warrants expire.  The approval of Rutherin will also have been preceded with a list of uses including the subject of ...more  
Comment by CancerSlayer on Aug 21, 2024 7:13pm
I feel you pain Tarbaby...the recent NRs in total represent incredible IP value (at minimum ) for such a small biotech.  Many standard investors cannot connect the dots at this stage, so consequently they'll wait to dive in until they see bigger signals of success & what I believe is inevitable, BTD & FDA approval.  But you & I know better... As for Rutherrin, that ...more  
Comment by Galaxym31 on Aug 21, 2024 8:57pm
ubiquitous    existing or being everywhere at the same time    A very cool word great for scrabble  omnipotent another great word   having unlimited power and able to do anything:  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250